Key takeaway: The investor presentation for Jubilant Ingrevia Limited (JUBLINGREA) for Q2 FY27 highlights strong financial performance, with revenue growing 24% year-on-year (YoY) to ₹1,394 crore and EBITDA rising 51% YoY to ₹221 crore. The company reported a 25% YoY revenue increase and 44% EBITDA growth in H1 FY27. Key drivers include disciplined execution of the Pinnacle strategy, improved pricing in Specialty Chemicals and Chemical Intermediates, and strong volume growth in Nutrition and Human Nutrition segments. The acquisition of a 40% stake in ZettaOne Technologies Limited was announced, aiming to expand into the Electronics Development and Manufacturing Services (EDMS) space. Specialty Chemicals saw 16% YoY revenue growth, driven by Fine Chemicals and CDMO segments, while Nutrition & Health Solutions reported 50% YoY revenue growth. Chemical Intermediates revenue rose 24% YoY, with EBITDA up 226% YoY. The company noted challenges in Agrochemicals due to China's overcapacity and muted pricing, but expressed confidence in sustaining growth across all segments in FY27, supported by plant closures in Europe and a new Multi-Purpose Plant nearing commissioning. Management emphasized strategic priorities, including diversified sourcing, strong customer partnerships, and agile operations to navigate global uncertainties.

Key takeaway: During the earnings conference call for Q1 FY27, management reported a strong financial performance with revenue growth of 25% year-on-year and a 36% increase in EBITDA. The company highlighted resilience in demand across the chemical industry despite geopolitical uncertainties. Pharmaceuticals were noted as a key growth driver, with stable momentum in agrochemicals and healthy growth in the Nutrition and Personal Care markets. Management provided updates on their CDMO and Fine Chemicals pipeline, indicating a strong opportunity funnel with over 100 molecules. They also discussed operational achievements, including successful integration of Remidex Pharma and recognition for safety and workplace quality. Management set a goal for continued growth driven by Specialty Chemicals and Nutrition, alongside a recovery in acetyls, while maintaining guidance for EBITDA in the range of INR750 crore to INR800 crore for the year.

Key takeaway: Jubilant Ingrevia Limited reported strong financial results for the quarter ended June 30, 2026, with revenue increasing by 25% year-over-year to ₹1,300 crore and EBITDA rising by 37% to ₹209 crore. Management highlighted the resilience of demand in the chemical industry despite geopolitical uncertainties, particularly in pharmaceuticals and agrochemicals. The Nutrition and Personal Care segments also showed healthy growth, driven by higher realizations for key products. The company noted stable momentum in its Specialty Chemicals and Chemical Intermediates segments, with significant growth in the latter, which saw a 240% increase in EBITDA. Management emphasized the progress of their Pinnacle strategy, which aims to enhance growth through improved operational efficiencies and a robust opportunity pipeline. The new Multi-Purpose Plant is on track for commissioning by the end of the year, further supporting growth in CDMO and Fine Chemicals.

Key takeaway: Management reported a strong performance for Q4 and FY '26, highlighting the highest quarterly revenue and EBITDA in 14 quarters, with a revenue of Rs. 1,179 crore, up 12% year-on-year. EBITDA increased by 11% year-on-year to Rs. 172 crore. The Specialty Chemicals segment achieved a revenue of Rs. 516 crore, reflecting a 6% year-on-year growth. Management noted effective handling of the Middle East crisis, resulting in no production loss. The company completed the acquisition of Remidex Pharma to enhance its Human Nutrition business. Management set a goal of at least 20% year-on-year growth in EBITDA for FY '27, supported by strong demand across segments, particularly in Specialty Chemicals and Nutrition. The construction of the Gajraula MPP plant is progressing well, and management emphasized the importance of their Pinnacle Journey strategy in driving future growth.

Key takeaway: Jubilant Ingrevia Limited reported its financial results for Q4 and FY26, highlighting a 12% year-on-year revenue growth and an 11% increase in EBITDA for the quarter. Management noted effective handling of the Middle East crisis, resulting in no production loss. The company announced a final dividend of ₹2.50 per share, totaling ₹5 per share for FY26. Key growth drivers included strong performance in pharmaceuticals and agrochemicals, with notable volume growth in nutrition and personal care markets. The company completed the acquisition of Remidex Pharma to enhance its human nutrition segment. Management indicated that early outcomes from their Pinnacle journey are visible, with improved customer relationships and a robust opportunity pipeline. The company aims for continued growth in FY27, particularly in specialty chemicals and nutrition, while also progressing with the construction of a new multi-purpose plant.

Key takeaway: Management reported on the financial results for the third quarter and nine months of FY '26, highlighting that the Specialty Chemicals segment continued to drive growth, with a double-digit increase in EBITDA. The Nutrition business maintained volume growth across core products, while the Chemical Intermediates segment recorded year-on-year volume growth despite pricing pressures. Overall, revenue increased by 3% and EBITDA rose by 8% year-to-date. Management noted challenges due to softer pricing across all segments but emphasized strong volume growth that helped stabilize performance. An interim dividend of 250% was announced. The company is optimistic about future growth, driven by new projects and market opportunities, particularly in the CDMO segment. Management also highlighted ongoing cost initiatives and sustainability efforts that contributed to operational efficiency.